Stifel initiated coverage of Tectonic Therapeutic (TECX) with a Buy rating and $75 price target The firm thinks the risk/reward ahead of the Phase 2 APEX data due in late 2026 to early 2027 is “compelling” and remains “cautiously optimistic” that Tectonic has a fundamentally better drug and trial than in prior relaxin failures, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECX: